| Date | Title | Description |
| 22.03.2024 | Lenmeldy Sparks Controversy as World's Most Expensive Medicine, Debating the $4.25 Million Price Tag | Inno Flores, Tech Times 22 March 2024, 09:03 pm
The introduction of Lenmeldy has sparked debates over its justification as the world's most expensive medicine. This groundbreaking gene therapy involves using the patient's own stem cells to ... |
| 18.03.2024 | Gene Therapy Is Now First FDA-Approved Treatment for Rare & Fatal CNS Disorder | A genetic medicine at the heart of a $387 million Kyowa Kirin acquisition has won FDA approval, a regulatory decision that makes the one-time treatment the first approved therapy for the rare inherited disorder metachromatic leukodystrophy ... |
| 18.03.2024 | FDA greenlights Orchard’s gene therapy Lenmeldy for rare and fatal disease | - |
| 13.11.2023 | Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments | Reported $5.6 million in quarterly Libmeldy net revenue and $12.7 million year-to-date
Planned acquisition by Kyowa Kirin valued at up to $477.6 million with an anticipated closing in the first quarter of 2024
Biologics License Application ... |
| 08.03.2023 | Orchard Therapeutics announces strategic financing totalling up to $188m | |
| 06.03.2023 | Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million | - |
| 05.01.2023 | Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH | BOSTON and LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics ORTX, a global gene therapy leader, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for OTL-203... |
| 21.12.2022 | Gene therapy trial shows promise for treating ‘bubble boy’ syndrome. Now comes the hard part | H.T. Begay is a happy kid. He’s smiley, silly, and definitely trying to make you laugh. The four-year-old’s two neat braids of dark hair wave behind him as he runs among the dust, dogs, and sheep near his family’s ranch on their Navajo rese... |
| 13.01.2022 | J.P. Morgan 2022: Reaching New Heights, Looking to New Horizons | Reaching New Heights, Looking to New Horizons
Bobby Gaspar, M.D., Ph.D., chief executive officer
40th Annual J.P. Morgan Healthcare Conference
January 13, 2022
From Clinician to CEO: The Evolution of HSC Gene Therapy
Photo courtesy of Great... |
| 05.11.2021 | Investor Deck – November 2021 | Corporate Presentation
November 2021
Forward-looking Statements
Certain information set forth in this presentation and in statements made orally during this presentation contains "forward-looking statements". Except for statements... |
| 12.08.2021 | In rare disease research, patient-centered clinical trial design is key | Since the introduction of the 21st Century Cures Act nearly five years ago, policymakers, regulators, advocates, and researchers have been working together to enhance the way experimental medicines are developed and assessed by placing a gr... |
| 01.07.2021 | Orchard Therapeutics : and Pharming HAE Collaboration | Joint analyst call: Orchard Therapeutics & Pharming Group
Dr Sijmen de Vries, CEO, Pharming Group Dr Anurag Relan, CMO, Pharming Group Dr Bobby Gaspar, CEO, Orchard Therapeutics
1 July 2021
Forward-looking Statements
This presentation m... |
| 03.03.2021 | Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of Libmeldy™ | MINNEAPOLIS--(BUSINESS WIRE)--Mar 3, 2021--
Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced an expansion of their multi-year partnership wit... |
| 05.02.2021 | Orchard Therapeutics Announces $150 Million Strategic Financing Strengthened Financial Position Supports Execution into the First Half of 2023 | - |
| 22.12.2020 | Orchard Therapeutics Receives EC Approval for Treatment of Early-Onset Metachromatic Leukodystrophy | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, notes that portfolio company Orchard Therapeutics, a global leader in gene therapy, announced... |
| 15.07.2020 | Biohaven recruits a Kardashian to help sell migraine drug; GSK licenses lentiviral tech to Orchard | → Biohaven has enlisted the help of Khloé Kardashian to help promote their newly approved migraine drug Nurtec. She’ll be leading a virtual campaign to endorse the drug by empowering “people with migraine to share their s... |
| 10.10.2019 | Female founders are more likely than men to attract later-stage VC funding | Female founders are more likely than men to attract later-stage venture capital funding, according to a new report from the Female Founders Forum.
The data from the UK shows that, once funded, the percentage of startups with a female founde... |
| 16.04.2019 | Data Supports Achievement of Proof-of-Concept Milestone for OTL-300 | Orchard Therapeutics has announced the achievement of clinical proof-of-concept based on data from the trial of OTL-300, for the treatment of transfusion-dependent beta-thalassemia (TDT). |
| 11.04.2019 | 10 successful female-led tech startups from London which got the maximum funding so far | Women entrepreneurs are increasing in number unlike ever before. They have busted stereotypes and are striving to bring about progressive changes in the business ecosystem. The quench for success has made them cross all roadblocks and lead ... |
| 28.02.2019 | Orchard Therapeutics achieves 100% survival rate during trial treatment for ADA-SCID | ADA-SCID is a rare, life-threatening, inherited disease caused by mutations in the ADA gene. Patients with ADA-SCID are unable to fight off and frequently succumb to complications from bacterial, viral and fungal infections. |
| 22.02.2019 | 4BIO portfolio company Orchard Therapeutics announces ADA-SCID follow-on results | Orchard Therapeutics plc (Nasdaq:ORTX) presents Two-Year Follow-Up Data versus historical control from Registrational Trial of OTL-101 for the Treatment of ADA-SCID. 100% overall survival and 100% event free survival in patients treated wit... |
| 05.11.2018 | Orchard Therapeutics Announces Closing of $225 Million Initial Public Offering, Including the Partial Exercise of Underwriters’ Option | - |
| 05.11.2018 | Orchard Therapeutics Closes $225M Initial Public Offering | Orchard Therapeutics plc (Nasdaq: ORTX), a Boston, Mass., USA and London, UK-based biopharmaceutical company focused on patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies, closed its initial p... |
| 05.11.2018 | Orchard Therapeutics announces closing of $225 Million Initial Public Offering | - |
| 01.11.2018 | Orchard Therapeutics Prices Initial Public Offering | Orchard Therapeutics plc (Nasdaq: ORTX), a biopharmaceutical company dedicated to improving the conditions of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies, priced its initial public offe... |
| 05.10.2018 | Orchard Therapeutics plans $172.5 million U.S. IPO | - |
| 05.10.2018 | Two months after closing a Series C round, Orchard Therapeutics files for $172.5M IPO | In April, Orchard acquired British drugmaker GlaxoSmithKline’s rare disease gene therapy portfolio, including Strimvelis, which the EMA approved in May 2016 for adenosine deaminase severe combined immunodeficiency, or ADA-SCID. ADA-SCID is ... |
| 15.08.2018 | Term Sheet — Wednesday, August 15 | IPO COMING SOON
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
According to a Bloomberg report, the company could raise as much as $3 billion in a public offering. Bitmain’s CEO plans to fil... |
| 14.08.2018 | Orchard Therapeutics Nabs $150M Series C |
BOSTON, MA, Orchard Therapeutics has raised a further $150 million to fund its work in gene therapy, building on earlier fundraisings worth more than $140 million.
>> Click here for more funding data on Orchard Therapeutics
>&g... |
| 13.08.2018 | Orchard Therapeutics closes $150 million Series C round | The company plans to use the money to advance its three leading clinical programs, namely OTL-101 for adenosine deaminase severe combined immunodeficiency, also known as ADA-SCID; OTL-200 for metachromatic leukodystrophy, or MLD; and OTL-10... |
| 13.08.2018 | Orchard Therapeutics Announces $150 Million Series C Financing to Advance Gene Therapy Pipeline | - |
| 13.08.2018 | 4BIO portfolio company Orchard Therapeutics Announces $150 Million Series C Financing | Orchard Therapeutics, a leading commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the completion of an oversubscribed $150 million Series C financi... |
| 13.08.2018 | Orchard Therapeutics Raises $150M in Series C Financing | Orchard Therapeutics, a London, United Kingdom-based company developing gene therapies, completed a $150m Series C financing.
The round was led by Deerfield Management with new investments from RA Capital Management, Venrock, Foresite Capit... |
| 20.12.2017 | 4BIO Capital participates in $110M Series B Financing of Orchard Therapeutics | Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced the completion of an oversubscribed $110 million (£85 million) Series B fin... |
| 20.12.2017 | Orchard Therapeutics Raises $110M in Series B Financing | Orchard Therapeutics, a London, UK- and California, US-based biotechnology company dedicated to treating rare disorders through innovative gene therapies, completed a $110m (£85m) Series B financing.
The round was co-led by Baillie Gifford ... |
| 20.12.2017 | Orchard Therapeutics raises $110m from Baillie Gifford, ORI Capital, Singapore’s Temasek | Premium
Orchard Therapeutics said on Wednesday it raised $110 million in the second round of funding as the drug developer looks to launch its gene therapy to treat a rare inherited disorder and beef up manufacturing facilities.
Continue re... |
| 03.05.2016 | Orchard Therapeutics launches with £21-million series A funding round | As part of its launch, Orchard Therapeutics' has announced formal partnerships with UCL, Great Ormond Street Hospital for Children NHS Foundation Trust (“GOSH”), University of California Los Angeles (“UCLA”), The University of Manchester an... |
| 03.05.2016 | Orchard Therapeutics launches, raises $33M, will face off with GSK | Orchard Therapeutics burst into life today with a little seed money and backing from several major hospitals and universities as it looks to take on the challenging but potentially lucrative world of ex vivo gene therapy research.
The clini... |
| - | Orchard Therapeutics closes $150 million Series C round | A company developing gene therapies for rare disorders has raised a large round of financing only months after it purchased a portfolio of therapy candidates from British drugmaker GlaxoSmithKline.
Orchard Therapeutics said Monday that it h... |
| - | The genetic medicine revolution is here — it’s time to build a regulatory framework for the future | Gene and cell therapy have moved from the realm of science fiction to medical reality. These new therapies have the potential to permanently correct genetic disorders with a single administration.
But for the potential of gene and cell ther... |
| - | Two months after closing a Series C round, Orchard Therapeutics files for $172.5M IPO | A company that markets the first gene therapy to win European Medicines Agency approval has filed for an initial public offering.
London-based Orchard Therapeutics is looking to become the next biotechnology company to go from a big venture... |
| - | Considerations in commercializing HSC gene therapies for rare disease | By Braden Parker, Chief Commercial Officer
This article was originally published as a Guest Column on Cell & Gene.
The transformative potential of gene therapy is bringing renewed hope to the rare disease community, but with scientific ... |
| - | Evolving the Newborn Screening system is key to realizing the full potential of genetic medicines | There are an estimated 7,000 rare diseases known today — a disproportionate number of which impact infants and children. These diseases are severe, often fatal, and place an enormous emotional and financial burden on patients, families, and... |
| - | On the frontier of gene therapy, new possibilities emerge | Researchers investigating a potential new therapy for an ultra-rare genetic disease have made an important discovery — one that could have broader implications and may lead to a lasting treatment for a severe, debilitating form of Crohn’s d... |
